Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Mendota Financial Group LLC

Mendota Financial Group LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 15.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,224 shares of the biopharmaceutical company’s stock after selling 393 shares during the period. Mendota Financial Group LLC’s holdings in Halozyme Therapeutics were worth $106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at about $49,000. GAMMA Investing LLC lifted its holdings in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the period. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $65,000. Finally, Park Place Capital Corp raised its position in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the topic of several recent research reports. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday. HC Wainwright boosted their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $54.14 on Tuesday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The firm has a market capitalization of $6.89 billion, a PE ratio of 17.93, a P/E/G ratio of 0.44 and a beta of 1.24. The business’s 50 day moving average price is $50.05 and its 200-day moving average price is $54.05.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.